Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 20INDUSTRY 20NIH 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

Radiotherapy 13Cisplatin 8Cytarabine 7carfilzomib 5Specimen Handling 5Paclitaxel 5Dexamethasone 5Methotrexate 4Lapatinib 4Gemcitabine 4Fluorouracil 4Docetaxel 4Brachytherapy 4Biopsy 4venetoclax 3pomalidomide 3Temozolomide 3Radiotherapy, Conformal 3Leucovorin 3Irinotecan 3Etoposide 3Cyclophosphamide 3Carboplatin 3neratinib 2merphos 2Vincristine 2Radiation 2Polymerase Chain Reaction 2Oxaliplatin 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × pomalidomide × Clear all
NCT03732703 2025-02-14

MyDRUG

Multiple Myeloma Research Consortium

Phase 1/2 Completed
103 enrolled
Plasma cell

Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Multiple Myeloma Research Consortium

Phase 1/2 Terminated
14 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02185820 2023-07-03

CPD

European Myeloma Network B.V.

Phase 1/2 Completed
57 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡